No Data
No Data
Lushang Freda Pharmaceutical (600223.SH): No plans to produce functional drinks at the moment.
Lushang Freda pharmaceutical (600223.SH) stated on its interactive platform on August 5th that the company currently has no plans to produce functional beverage products.
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Goes Ex-Dividend In Just Two Days
Lushang Freda Pharmaceutical (600223.SH) will distribute an annual equity of 0.1 yuan per share in 2023. The stock registration will be on July 30th.
Lushang Freda Pharmaceutical (600223.SH) has released its annual equity distribution implementation announcement for 2023, and this profit distribution plan is based on...
Swhy: The penetration rate continues to increase coupled with the rise of domestic products, bullish on the cosmetic and medical beauty sector.
The medical beauty industry will continue to benefit from a rich supply of products and maintain healthy development through industry standardization.
Lushang Freda Pharmaceutical (600223.SH) currently does not conduct direct sales business.
Lushang Freda pharmaceutical (600223.SH) stated on the interactive platform on July 5 that the company is currently not engaged in direct sales business and has not cooperated with any company to use its license.
CITIC Securities: the collagen industry's prosperity continues with significant growth among various leading companies, and there is ample potential for the future.
According to the Zhitong Finance APP, Citic Securities research report believes that the sales of restructured collagen products have been excellent, with brands such as Weweima, Kelifu, and Viyimi performing well this year.
No Data